Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
Sign Up to like & getrecommendations! Published in 2022 at "Chemmedchem"
DOI: 10.1002/cmdc.202200548
Abstract: Androgen receptor targeted therapies for prostate cancer have serious limitations in advanced stages of the disease. While resistance to the FDA‐approved enzalutamide is extensively documented, novel therapies based on epichlorohydrin scaffolds (EPI) are currently in… read more here.
Keywords: epi 001; androgen receptor; prostate cancer; enzalutamide epi ... See more keywords